OverviewSuggest Edit

Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company offers TL-532, new cancer immunotherapy to treat various types of cancer. TL-532 is a structurally defined double-stranded RNA, produced synthetically, and highly specific to the TLR3 receptor.
HQLyon, FR

Latest Updates

Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Tollys Office Locations

Tollys has an office in Lyon
Lyon, FR (HQ)
41 Quai Fulchiron
Show all (1)

Tollys Financials and Metrics

Summary Metrics

Founding Date


Tollys total Funding

$6.8 m

Tollys latest funding size

$2.5 m

Time since last funding

2 years ago
Tollys's latest funding round in May 2020 was reported to be $2.5 m. In total, Tollys has raised $6.8 m
Show all financial metrics

Tollys Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Tollys Online and Social Media Presence

Embed Graph

Tollys News and Updates

Tollys Raises €2.3M in Series A Financing

Tollys, a Lyon, France-based developer of a synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, closed a Series A round of financing totaling €2.3m ($2.5M). This brings the total amount raised to €6.4M ($6.8M) since the company was founded in 2015.

Tollys Frequently Asked Questions

  • When was Tollys founded?

    Tollys was founded in 2015.

  • Who are Tollys competitors?

    Competitors of Tollys include Priothera, Remegen and GenFleet Therapeutics.

  • Where is Tollys headquarters?

    Tollys headquarters is located at 41 Quai Fulchiron, Lyon.

  • Where are Tollys offices?

    Tollys has an office in Lyon.

  • How many offices does Tollys have?

    Tollys has 1 office.